Phase 3 Randomized Study of Subcutaneous Daratumumab Versus Active Monitoring in High-Risk Smoldering Multiple Myeloma Patients

The primary objective of this Phase 3 randomized, multicenter study is to evaluate whether treatment with **daratumumab** administered subcutaneously prolongs progression-free survival (PFS) compared with active monitoring in subjects with high-risk smoldering multiple myeloma. This is clinically relevant as prolonging PFS can delay the progression to symptomatic multiple myeloma, potentially improving patient outcomes and quality of life.

The clinical trial involves a total of **192 participants** diagnosed with a **precancerous form of blood cancer in the bone marrow**, specifically high-risk smoldering multiple myeloma (SMM). The study population includes both male and female subjects, aged 18 years and older, with no upper age limit specified. Participants were selected based on their diagnosis of SMM for five years or less, with measurable disease and specific laboratory criteria, including serum M protein and bone marrow plasma cell levels. The trial includes individuals with an Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1, indicating they are fully active or restricted in physically strenuous activity but ambulatory. The study population is considered vulnerable, and participants must adhere to specific lifestyle considerations, such as contraceptive use, to prevent pregnancy during and after the trial. The selection criteria ensure that participants are willing and able to comply with the study's prohibitions and restrictions, as outlined in the protocol.

The clinical trial is a **Phase 3 randomized, double-blind, controlled study** designed to evaluate the efficacy of **daratumumab** administered subcutaneously in comparison to active monitoring in subjects with high-risk smoldering multiple myeloma, a precancerous form of blood cancer in the bone marrow. The primary objective is to determine whether treatment with daratumumab prolongs progression-free survival (PFS) compared to active monitoring. The trial is expected to run from November 2017 to December 2025, with participant involvement lasting up to 36 months, depending on individual response and progression.

Participants will undergo a series of study visits, beginning with an inclusion (screening) visit to assess eligibility based on criteria such as age, diagnosis, and clinical laboratory values. Following randomization, participants will receive either the investigational product or be placed under active monitoring. Regular follow-up visits will be scheduled to monitor safety, efficacy, and pharmacokinetics, with assessments including laboratory tests and clinical evaluations. The end-of-study visit will conclude the participant's involvement, where final assessments will be conducted to evaluate the overall outcomes of the treatment.

Participants may be withdrawn from the study early if they experience disease progression to multiple myeloma, as defined by the International Myeloma Working Group diagnostic criteria, or if they encounter significant adverse events that compromise safety. Additionally, non-compliance with study protocols or withdrawal of consent will also result in early termination from the study. The trial is conducted in accordance with ethical standards and regulatory requirements, ensuring the safety and well-being of all participants throughout the study duration.

The clinical trial involves the administration of the experimental medication **daratumumab**, marketed under the product name JNJ-54767414. This medication is provided in the form of an **injection** and is intended for **subcutaneous use**. The maximum daily dose of daratumumab is 1800 mg, with the same amount being the maximum total dose per administration. The treatment period is set to a maximum of 36 months. Daratumumab is a protein-based therapeutic agent, specifically classified under "Protein - Other," and is developed by Janssen-Cilag International N.V. The medication is not formulated for pediatric use and has been designated as an orphan drug under the designation number EU/3/13/1153.

In this study, the experimental treatment with daratumumab is compared against a non-experimental treatment, which is active monitoring. Active monitoring serves as the comparator treatment and involves regular observation and assessment of the participants' condition without the administration of any therapeutic intervention. This approach is utilized to evaluate the efficacy of daratumumab in prolonging progression-free survival in subjects with high-risk smoldering multiple myeloma. Participant compliance with the dosing schedule and administration route is monitored throughout the trial to ensure adherence to the study protocol.

The efficacy of the clinical trial will be assessed by evaluating the **progression-free survival (PFS)** of participants. PFS is defined as the time from the date of randomization to the date of initial documented progression to multiple myeloma (MM) according to the International Myeloma Working Group (IMWG) diagnostic criteria for MM or the date of death, whichever occurs first. This primary endpoint will be used to determine whether treatment with subcutaneously administered daratumumab prolongs PFS compared to active monitoring in subjects with high-risk smoldering multiple myeloma (SMM).